• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

腺苷 A(2A)受体与 ZM241385、黄嘌呤衍生物 XAC 和咖啡因复合物的结构。

Structure of the adenosine A(2A) receptor in complex with ZM241385 and the xanthines XAC and caffeine.

机构信息

Heptares Therapeutics Ltd, BioPark, Welwyn Garden City, Herts, AL7 3AX, UK.

出版信息

Structure. 2011 Sep 7;19(9):1283-93. doi: 10.1016/j.str.2011.06.014.

DOI:10.1016/j.str.2011.06.014
PMID:21885291
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3732996/
Abstract

Methylxanthines, including caffeine and theophylline, are among the most widely consumed stimulant drugs in the world. These effects are mediated primarily via blockade of adenosine receptors. Xanthine analogs with improved properties have been developed as potential treatments for diseases such as Parkinson's disease. Here we report the structures of a thermostabilized adenosine A(2A) receptor in complex with the xanthines xanthine amine congener and caffeine, as well as the A(2A) selective inverse agonist ZM241385. The receptor is crystallized in the inactive state conformation as defined by the presence of a salt bridge known as the ionic lock. The complete third intracellular loop, responsible for G protein coupling, is visible consisting of extended helices 5 and 6. The structures provide new insight into the features that define the ligand binding pocket of the adenosine receptor for ligands of diverse chemotypes as well as the cytoplasmic regions that interact with signal transduction proteins.

摘要

甲基黄嘌呤,包括咖啡因和茶碱,是世界上使用最广泛的兴奋剂药物之一。这些作用主要通过阻断腺苷受体来介导。具有改善特性的黄嘌呤类似物已被开发为治疗帕金森病等疾病的潜在药物。在这里,我们报告了一个热稳定的腺苷 A(2A)受体与黄嘌呤胺同系物和咖啡因的复合物的结构,以及 A(2A)选择性反向激动剂 ZM241385 的结构。该受体以所谓的离子锁存在的非活性状态构象结晶。负责 G 蛋白偶联的完整的第三胞内环可见,由延伸的螺旋 5 和 6 组成。这些结构为不同化学型配体的腺苷受体配体结合口袋的特征以及与信号转导蛋白相互作用的细胞质区域提供了新的见解。

相似文献

1
Structure of the adenosine A(2A) receptor in complex with ZM241385 and the xanthines XAC and caffeine.腺苷 A(2A)受体与 ZM241385、黄嘌呤衍生物 XAC 和咖啡因复合物的结构。
Structure. 2011 Sep 7;19(9):1283-93. doi: 10.1016/j.str.2011.06.014.
2
Agonist-bound adenosine A2A receptor structures reveal common features of GPCR activation.激动剂结合的腺苷 A2A 受体结构揭示了 G 蛋白偶联受体激活的共同特征。
Nature. 2011 May 18;474(7352):521-5. doi: 10.1038/nature10136.
3
Computational study of the binding modes of caffeine to the adenosine A2A receptor.咖啡因与腺苷 A2A 受体结合模式的计算研究。
J Phys Chem B. 2011 Dec 1;115(47):13880-90. doi: 10.1021/jp2022049. Epub 2011 Nov 9.
4
Structure of an agonist-bound human A2A adenosine receptor.激动剂结合的人 A2A 腺苷受体结构。
Science. 2011 Apr 15;332(6027):322-7. doi: 10.1126/science.1202793. Epub 2011 Mar 10.
5
Structures of Human A and A Adenosine Receptors with Xanthines Reveal Determinants of Selectivity.人 A 和 A 腺苷受体与黄嘌呤结构揭示了选择性的决定因素。
Structure. 2017 Aug 1;25(8):1275-1285.e4. doi: 10.1016/j.str.2017.06.012. Epub 2017 Jul 14.
6
Controlling the Dissociation of Ligands from the Adenosine A2A Receptor through Modulation of Salt Bridge Strength.通过调节盐桥强度控制配体与腺苷A2A受体的解离
J Med Chem. 2016 Jul 14;59(13):6470-9. doi: 10.1021/acs.jmedchem.6b00653. Epub 2016 Jul 1.
7
Molecular Basis of Ligand Dissociation from the Adenosine A2A Receptor.腺苷A2A受体配体解离的分子基础
Mol Pharmacol. 2016 May;89(5):485-91. doi: 10.1124/mol.115.102657. Epub 2016 Feb 12.
8
Ligand binding and subtype selectivity of the human A(2A) adenosine receptor: identification and characterization of essential amino acid residues.人 A(2A) 腺苷受体的配体结合和亚型选择性:必需氨基酸残基的鉴定和特征描述。
J Biol Chem. 2010 Apr 23;285(17):13032-44. doi: 10.1074/jbc.M109.096974. Epub 2010 Feb 10.
9
Thermostabilisation of an agonist-bound conformation of the human adenosine A(2A) receptor.激动剂结合态人源腺苷 A(2A)受体的热稳定性。
J Mol Biol. 2011 Jun 10;409(3):298-310. doi: 10.1016/j.jmb.2011.03.075. Epub 2011 Apr 9.
10
The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist.与拮抗剂结合的人A2A腺苷受体的2.6埃晶体结构。
Science. 2008 Nov 21;322(5905):1211-7. doi: 10.1126/science.1164772. Epub 2008 Oct 2.

引用本文的文献

1
Structural basis of the residence time of adenosine A receptor ligands revealed by NMR.核磁共振揭示腺苷A受体配体停留时间的结构基础
Chem Sci. 2025 Aug 29. doi: 10.1039/d5sc02398j.
2
Molecular basis of ligand binding and receptor activation at the human A adenosine receptor.人类A1腺苷受体配体结合及受体激活的分子基础
Nat Commun. 2025 Aug 18;16(1):7674. doi: 10.1038/s41467-025-62872-x.
3
Identification of nanomolar adenosine A receptor ligands using reinforcement learning and structure-based drug design.利用强化学习和基于结构的药物设计鉴定纳摩尔级别的腺苷 A 受体配体。

本文引用的文献

1
Agonist-bound adenosine A2A receptor structures reveal common features of GPCR activation.激动剂结合的腺苷 A2A 受体结构揭示了 G 蛋白偶联受体激活的共同特征。
Nature. 2011 May 18;474(7352):521-5. doi: 10.1038/nature10136.
2
Thermostabilisation of an agonist-bound conformation of the human adenosine A(2A) receptor.激动剂结合态人源腺苷 A(2A)受体的热稳定性。
J Mol Biol. 2011 Jun 10;409(3):298-310. doi: 10.1016/j.jmb.2011.03.075. Epub 2011 Apr 9.
3
Structure of an agonist-bound human A2A adenosine receptor.激动剂结合的人 A2A 腺苷受体结构。
Nat Commun. 2025 Jul 1;16(1):5485. doi: 10.1038/s41467-025-60629-0.
4
Enhancing binding affinity predictions through efficient sampling with a re-engineered BAR method: a test on GPCR targets.通过使用重新设计的BAR方法进行高效采样来增强结合亲和力预测:对GPCR靶点的测试
Chem Sci. 2025 May 21. doi: 10.1039/d5sc01030f.
5
Inactive structures of the vasopressin V2 receptor reveal distinct binding modes for Tolvaptan and Mambaquaretin toxin.血管加压素V2受体的非活性结构揭示了托伐普坦和曼巴夸雷汀毒素的不同结合模式。
Nat Commun. 2025 Apr 24;16(1):3899. doi: 10.1038/s41467-025-59114-5.
6
Structural insights into small-molecule agonist recognition and activation of complement receptor C3aR.小分子激动剂识别与补体受体C3aR激活的结构见解
EMBO J. 2025 May;44(10):2803-2826. doi: 10.1038/s44318-025-00429-w. Epub 2025 Apr 7.
7
Minute-timescale free-energy calculations reveal a pseudo-active state in the adenosine A receptor activation mechanism.分钟时间尺度的自由能计算揭示了腺苷A受体激活机制中的一种假活性状态。
Chem. 2024 Dec 12;10(12):3678-3698. doi: 10.1016/j.chempr.2024.08.004.
8
Structure and function of a near fully-activated intermediate GPCR-Gαβγ complex.一种接近完全激活的中间态G蛋白偶联受体-Gαβγ复合物的结构与功能
Nat Commun. 2025 Jan 28;16(1):1100. doi: 10.1038/s41467-025-56434-4.
9
Discovery of the First Efficacious Adenosine 2A Receptor Negative Allosteric Modulators for High Adenosine Cancer Immunotherapies.发现用于高效腺苷癌症免疫疗法的首个有效腺苷2A受体负变构调节剂。
J Med Chem. 2025 Feb 27;68(4):4059-4078. doi: 10.1021/acs.jmedchem.4c01691. Epub 2025 Jan 24.
10
Photoswitch dissociation from a G protein-coupled receptor resolved by time-resolved serial crystallography.通过时间分辨连续晶体学解析光开关与G蛋白偶联受体的解离。
Nat Commun. 2024 Dec 30;15(1):10837. doi: 10.1038/s41467-024-55109-w.
Science. 2011 Apr 15;332(6027):322-7. doi: 10.1126/science.1202793. Epub 2011 Mar 10.
4
The structural basis of agonist-induced activation in constitutively active rhodopsin.激动剂诱导的固有激活状态视紫红质激活的结构基础。
Nature. 2011 Mar 31;471(7340):656-60. doi: 10.1038/nature09795. Epub 2011 Mar 9.
5
International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors--an update.国际基础和临床药理学联合会. LXXXI. 腺苷受体的命名和分类-更新。
Pharmacol Rev. 2011 Mar;63(1):1-34. doi: 10.1124/pr.110.003285. Epub 2011 Feb 8.
6
The structural basis for agonist and partial agonist action on a β(1)-adrenergic receptor.激动剂和部分激动剂在β(1)-肾上腺素能受体上作用的结构基础。
Nature. 2011 Jan 13;469(7329):241-4. doi: 10.1038/nature09746.
7
Structure of a nanobody-stabilized active state of the β(2) adrenoceptor.β2 肾上腺素能受体的纳米体稳定的活性状态结构。
Nature. 2011 Jan 13;469(7329):175-80. doi: 10.1038/nature09648.
8
Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist.人源多巴胺 D3 受体与 D2/D3 选择性拮抗剂复合物的结构。
Science. 2010 Nov 19;330(6007):1091-5. doi: 10.1126/science.1197410.
9
Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists.小分子和环肽拮抗剂与 CXCR4 趋化因子 GPCR 的结构。
Science. 2010 Nov 19;330(6007):1066-71. doi: 10.1126/science.1194396. Epub 2010 Oct 7.
10
Preladenant, a novel adenosine A(2A) receptor antagonist for the potential treatment of parkinsonism and other disorders.普雷拉登特,一种新型腺苷A(2A)受体拮抗剂,用于帕金森病及其他疾病的潜在治疗。
IDrugs. 2010 Oct;13(10):723-31.